Is CG Oncology (CGON) stock Halal?

CG Oncology is a biotechnology company focusing on the development and commercialization of novel immuno-oncology therapies. The company's primary aim is to harness the power of oncolytic virus technologies to create innovative treatments for cancer patients. Cg Oncology targets high-priority therapeutic areas, notably bladder cancer, seeking to meet significant unmet medical needs. Its research and development efforts are geared towards integrating robust scientific expertise with advanced biotechnological processes to produce effective cancer therapies. Before any of that matters to a Muslim investor, one question comes first: is CG Oncology stock Halal?

Is CG Oncology Shariah compliant?

No. In the October 2026 screening CG Oncology (CGON) does not pass AAOIFI screening: it fails the non-permissible income screen. The Shariah case on a technology company like CG Oncology is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does CG Oncology pass the business activity test?

The activity screen is only part of the picture this month: CG Oncology currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is CG Oncology's income Halal?

No. CG Oncology's income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does CG Oncology meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $6.28B (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has CGON re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for CG Oncology?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing